PHARMACEUTICAL companies have been accused of making slight modifications to their drugs to extend a patent life span.
This has resulted in calls for the government to not recognise process methods for patenting, and allowing only molecular patents.
Already a subscriber? Log in
Play, subscribe and stand a chance to win prizes worth over RM39,000! T&C applies.
Cancel anytime. Ad-free. Unlimited access with perks.
